Oncternal Therapeutics (ONCT) has disclosed a new risk, in the Employment / Personnel category.
Oncternal Therapeutics faces potential risks associated with its workforce reduction strategy initiated in September 2024, as approved by its Board. The intended outcome of this reduction may not be achieved, potentially leading to significant adverse consequences such as loss of institutional knowledge, unintended employee attrition, and decreased morale. Furthermore, the company might struggle with distributing essential functions among remaining staff, hindering new opportunities and incurring additional costs to hire new personnel. If the anticipated benefits are not realized, the company’s business, financial condition, and operational results could be materially adversely affected.
The average ONCT stock price target is $10.00, implying 629.93% upside potential.
To learn more about Oncternal Therapeutics’ risk factors, click here.
